pdufa.bio
Home › Decisions › GILD 2026-02-06

GILD FDA decision — Feb 6, 2026

✓ APPROVED

Gilead Sciences Inc. — YESCARTA - Axicabtagene ciloleucel - (ZUMA-5 · Indolent B-Cell Non-Hodgkin Lymphoma.

Run-up into the decision (T-120 → T+5)

PDUFA 2/6/26$149.37$110.568/22/25
Daily close, T-120 (8/22/25) through T+5. Run-up high $149.37 on 2/5/26, low $110.56 on 10/8/25 (T-120 to T-1). FDA decision 2/6/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-02-06
OutcomeApproved
Drug / candidateYESCARTA - Axicabtagene ciloleucel - (ZUMA-5
CompanyGilead Sciences Inc.
120-day run-up (T-120→T-1)+26.2%
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio